CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02178787
NCT02178787N/ACompleted

UTLight-transcranial Doppler Assessment of Regional Cerebral Autoregulation

Beth Israel Deaconess Medical Center·observational·Posted Jul 1, 2014·Updated Jun 16, 2017

In Brief

An observational study for Diabetes. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Cerebral autoregulation (CA) is a complex mechanism that serves the essential and vital purpose of controlling cerebral blood flow and metabolism. A stable and optimal brain blood flow is imperative for normal brain function. Diabetes Mellitus (DM ) is associated with microvascular disease that alters CA and also with autonomic failure that may lead to orthostatic hypotension (OH). These conditions may lead to decreased brain blood flow in upright position. This observational study will compare two technologies that evaluate brain blood flow during standing up and other maneuvers in people with and without type 2 diabetes. These technologies are transcranial Doppler and UTLight technology (CerOx). This study will determine the safety and feasibility of CerOx technology for continuous monitoring of cerebral blood flow.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
CollaboratorsOrnim Medical Ltd.

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 1, 2014
Enrollment StartApr 1, 2014
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 12.0 years ago